Cannabis Law Report

JANUARY 24, 2022

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

JULY 6, 2021

Johnson’s primary area of research expertise is the psychopharmacology of medications for treating addictions, and he is well known in the field for his discovery that topiramate, a gamma-aminobutyric acid (GABA) facilitator and glutamate antagonist, an effective treatment for alcoholism. In 2019, Dr. Johnson received the R.

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

Cannabis Law Report

OCTOBER 15, 2021

The presentation details the identification of a novel locus on chromosome 14 which is associated with proteinuric kidney disease and includes data which confirms the well-known association of APOL1 risk haplotypes (i.e., New data supporting the use of machine learning and electronic health records to predict DN in patients with diabetes. “In

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Cannabis Law Report

DECEMBER 6, 2021

–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the appointment of Jeff W. Jacobs, Ph.D. as Chief Scientific Officer (CSO). Dr. Jacobs, who most recently served as CSO of Ardelyx, Inc.,

Research and Development 52

Research and Development Supply Chain Clinical Trials Medicine 52

Cannabis Law Report

DECEMBER 9, 2021

9, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. Thu, December 9, 2021, . NEW YORK , Dec. ” About MindMed.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. These treatments can be prescribed only by specialist doctors in a limited number of circumstances where other medicines have failed. What do experts say? September 23, 2019.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. What if most of it is not based on the level of scientific certainty that cannabis marketing teams and media outlets would have us believe? Recent data suggest the US science knowledge is about the global average.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. 14th at 11:00 a.m. PT (2:00 p.m.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

SEPTEMBER 15, 2021

This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. The FDA is aware of media reports of delta-8 THC products getting consumers “high.” brownies, gummies).

THC 105

THC Pets Events Hemp 105

Veriheal

AUGUST 17, 2021

In an official statement to media sources, Dr. Drake said ; “We don’t find any evidence to support the theory that cannabis functions as a gateway drug… if anything, we find that recreational cannabis legalization decreases opioid-related emergency department visits.” Marijuana is a gateway drug, really?

Data 98

Data Cannabis Media Collective 98

CannaMD

NOVEMBER 6, 2019

Perhaps the commercialization of marijuana and the favorable media coverage surrounding the health effects of marijuana are fostering such a perception. Results further indicate that the presence of medicinal cannabis legislation appears to have no influence over opioid misuse. Marijuana Preferred Over Pain Pills. million to 11.4

Marijuana 87

Marijuana Patients Clinical Trials Data 87

The Blunt Truth

MAY 26, 2020

However, enforcement, as it relates to CBD products and their claimed medicinal effects on COVID-19, is becoming increasingly apparent to industry watchers. To that end, the FDA followed up with another piece of public guidance in late April, informing the public that there are currently no approved treatments for COVID-19.

CBD 103

CBD Hemp Programs Food 103

Cannabis Law Report

DECEMBER 14, 2021

(NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”), announced today that it is the first company to formulate medical cannabis extract vaporizer pen products in a UK-based manufacturing premises, licensed and approved by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and Home Office.

Extraction 52

Extraction Patients Medicine Tincture 52

Cannabis Law Report

JULY 28, 2021

Active research includes applications of machine learning and data mining as a member of the University of Alberta computational psychiatry group. His knowledge and insight will be paramount as we continue to navigate the development of DMT as a treatment for addiction disorders,” said Chief Executive Officer, Timothy Ko.

Research and Development 105

Research and Development Events Media Data 105

Cannabis Law Report

MAY 6, 2022

The FDA’s warning letters tell the public that the FDA reads and reviews companies’ websites, labels, social media, and marketing language. The FDA evaluates sellers’ claims, graphics, and product descriptions – including products marketed for animals, information about food additives, and social media websites.

THC 52

THC CBD Media Food 52

Freedom Leaf

JANUARY 4, 2018

After months of development, my partner and I built and successfully launched the beta for our cannabis data-analytics software, Jade Insights. It’s a software platform that helps cannabis businesses augment their process by providing insights for data-backed decision-making. ” JOHN KAGIA. ” OPHELIA CHONG.

Data 60

Data Policy Media Cannabis 60

Veriheal

AUGUST 12, 2021

Funded by Realm of Caring —a non-profit organization committed to redefining cannabis through research and education—this study on CBD and epilepsy was carried out as part of a joint effort with Johns Hopkins University School of Medicine researchers. A specific type of CBD was focused on for the investigation.

Epilepsy 66

Epilepsy Pharmaceutical Patients Sleep 66

The Joint Blog

JULY 25, 2020

Lately, CBD has warranted a huge share of public and media attention for its perceived benefits to health and well-being. FDA on the Marketing of CBD Products The FDA is fully aware that several states have already passed laws allowing the use of CBD products for both recreational and medicinal purposes. CBD is everywhere these days.

CBD 33

CBD Clinical Trials Safety Media 33

Cannabis Law Report

JULY 24, 2019

1 We have also reviewed your social media websites at www.facebook.com/CuraleafHemp External Link Disclaimer and [link] External Link Disclaimer ; these websites direct consumers to your website, [link] External Link Disclaimer , to purchase your products.

CBD 51

CBD Tincture Pets Chronic Pain 51

Greenspoon Marder Cannabis Law Group Blog

APRIL 2, 2019

For example, we’re seeking comments, data and information on a variety of topics including: what levels of cannabis and cannabis-derived compounds cause safety concerns; how the mode of delivery (e.g., For Alzheimer’s patients, CBD is one treatment option that is slowing the progression of that disease.”.

CBD 40

CBD Research and Development Safety Therapy 40

Cannabis Law Report

JANUARY 20, 2022

Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines. Eleusis designed ELE-Psilo, a proprietary psilocybin-based drug candidate that is formulated for IV infusion and in development for the treatment of depression.

Therapy 52

Therapy Research and Development Business Access 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Consumers spent roughly $31.3 increase in annual sales.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JULY 20, 2019

In New Jersey, there are nearly 50,000 registered medical marijuana patients and only six Alternative Treatment Centers (ATCs) currently operating. Ability to provide appropriate research data. MEDIA CONTACT. By: Kristin Jordan , Senior Counsel. Kristin Jordan. Criterion 5. Patient education and counseling methods.

Law 40

Law Marijuana Education Cultivation 40

Cannabis Law Report

SEPTEMBER 29, 2021

Distinguished Professor of Psychiatry and Biobehavioral Sciences as well as Molecular and Medicinal Pharmacology at the Jane and Terry Semel Institute at David Geffen School of Medicine UCLA, and Richard De La Garza II, Ph.D., ANANDA Scientific Media Relations | Christopher Moore | 813 326 4265 | media@anandascientific.com.

Clinical Trials 52

Clinical Trials Medicine Treatment Research and Development 52

Cannabis Law Report

JANUARY 4, 2022

Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder. Clinical Trials.gov Identifier: NCT03787628 ).

Clinical Trials 52

Clinical Trials Treatment Research and Development Media 52

Cannabis Law Report

NOVEMBER 24, 2021

Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. Background. Conclusions.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

DECEMBER 9, 2021

Dr. Johnson recently reported his interim results at Microdose’s Psychedelic Medicine Business Event, from his current smoking cessation study, utilizing a single macro-dose of psilocybin. Mydecine has been working closely with Dr. Johnson and JHU to advance their lead drug candidate MYCO-001 as a smoking cessation treatment.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Miss Marijuana

JULY 30, 2019

Clearly for the sake of our health and youth, we need more memes and less social media trolls. . About a year ago, data from the Strainprint app was used to analyze the impact of marijuana on depression, anxiety and stress. The data came from close to 12,000 entries (that’s a huge sample size!). So what does this all mean?

Strains 12

Strains Data Cannabis THC 12

Veriheal

JANUARY 4, 2021

If you’re familiar with Kratom or cannabis and what their medicinal qualities are, you might be able to lend a helping hand to the man, the US Federal Government, that is. The AHRQ isn’t looking for solid input from the people in regard to the medicinal and therapeutic attributes of either of these two plants.

Chronic Pain 104

Chronic Pain Therapy Cannabinoids Treatment 104

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. “It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool.

Programs 108

Programs Research and Development Education Treatment 108

Cannabis Law Report

AUGUST 27, 2022

In the context of increasing media scrutiny and widespread public attention on celebrities for their arrest and detention resulting from the purported use of cannabis, the question as to whether cannabis consumption should be decriminalised has once again assumed significance. Appeals to Parliament.

Consumption 98

Consumption Cultivation Research and Development Cannabis 98

Alchimia

JANUARY 25, 2022

At the beginning of this new year of 2022, a news story about how cannabis can help fight COVID-19 was picked up by many non-cannabis media. While this research is certainly worth celebrating, the reality behind the message can be easily misunderstood in this age of social media. Cannabis as a treatment for COVID-19 infection.

Research and Development 98

Research and Development Terpenes CBD Treatment 98

The Cannigma

MARCH 2, 2022

Anthony is the founder of the Trav Media Group. EG: I’m here at the moment with Anthony Travagliante of Trav Media Group. I’ve always believed in it as a medicine. We were named differently back then now with Trav Media Group. Can you tell us a bit more about what you offer at the Trav Media Group across the board?

Wellness and Beauty 52

Wellness and Beauty Cannabis Media Patients 52

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. “It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool.

Programs 40

Programs Research and Development Education Treatment 40

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. published the first edition of the MAPS Bulletin , titled “ MDMA Can Become a Legal Medicine ,” and the FDA rejected the second MDMA study protocol submitted by MAPS.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

JUNE 4, 2021

there has never been a better time for new treatment options. Although psychedelics have been used by humans for over 7,000 years across multiple different cultures, only in the past century have these medicines been outlawed by governments around the world. This list is focused on those who have had the largest impact for 2021. .

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

Cannabis Law Report

SEPTEMBER 1, 2022

In July 2022, an observational study released by the Annals of Internal Medicine found that the most common patient-reported condition was chronic pain, accounting for 60.6% 1 reason patients seek medical cannabis is to augment their pain management treatment. “The data is clear. media@texasoriginal.com.

Chronic Pain 52

Chronic Pain Programs Patients Conditions 52